6 recruiting, 1 active not recruiting, 1 enrolling by invitation. 6 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 4, Active not recruiting 1, Enrolling by invitation 1 |
| Phase 2 | 4 | Recruiting 4 |
Follow Stephan Grupp MD PhD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Anti-CD123 LV redirected T cells (CART123), Ruxolitinib (JAKAVI®) - Acute Myeloid Leukemia (AML) | Phase 1 | Recruiting | Stephan Grupp MD PhD | 30 | 2026-05-14 | 2026-07-07 |
| Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases Depletion of CD3/CD19 in an autologous stem cell transplant - Systemic Lupus Erythematosus, Systemic Sclerosis | Phase 2 | Recruiting | Stephan Grupp MD PhD | 20 | 2026-03-01 | 2025-10-14 |
| PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma PHOX2B PC-CAR T Cells - Refractory Neuroblastoma, Relapsed Neuroblastoma | Phase 1 | Active not recruiting | Stephan Grupp MD PhD | 38 | 2025-06-20 | 2026-07-01 |
| Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma Allogeneic anti-CD7 CAR-T cells (BEAM-201) - T-Cell Acute Lymphoblastic Leukemia/Lymphoma | Phase 1 | Recruiting | Stephan Grupp MD PhD | 33 | 2025-04-29 | 2026-07-07 |
| GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma GPC2 CAR T cells - Refractory Neuroblastoma, Relapsed Neuroblastoma | Phase 1 | Enrolling by invitation | Stephan Grupp MD PhD | 45 | 2023-05-23 | 2026-08-14 |
| Co-administration of CART22-65s and huCART19 for B-ALL Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s), Autologous, humanized anti-CD19 CAR T cell therapy (huCART19) - B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Recruiting | Stephan Grupp MD PhD | 93 | 2023-01-25 | 2026-03-27 |
| Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19) - B Cell Acute Lymphoblastic Leukemia (B-ALL), B Lineage Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Recruiting | Stephan Grupp MD PhD | 115 | 2022-09-20 | 2026-05-26 |
| Orphan Indications for CD19 Redirected Autologous T Cells Murine CART19 - Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL, Infants With Very High Risk KMT2A B-ALL | Phase 2 | Recruiting | Stephan Grupp MD PhD | 133 | 2020-03-12 | 2026-03-06 |
Burkitt Lymphoma (2) · Neuroblastoma (2) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Leukemia, T-Cell (1) · Lupus Erythematosus, Systemic (1) · Lymphoma (1) · Lymphoma, T-Cell (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Retinoblastoma (1) · Scleroderma, Systemic (1)
ruxolitinib (1)
United States (8)
Stephan Grupp, MD, PhD (3) · Allison Barz Leahy, MD (1) · Amanda DiNofia, MD (1) · Caitlin Elgarten, MD (1) · Caroline Diorio, MD (1) · Jacquelyn Crane, MD (1) · Lisa Wray, MD (1) · Lucy Cain, MBBS (1) · Regina Myers, MD (1) · Stephan A. Grupp, MD, PhD (1) · Stephan Grupp, MD,PhD (1)
R37CA282041 (1)